Altamira Therapeutics Stock In The News
| CYTO Stock | USD 0.43 0.03 7.50% |
Our overall analysis of Altamira Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Altamira Therapeutics. The specific impact of Altamira Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Altamira Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Altamira Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Altamira Therapeutics Backtesting and Altamira Therapeutics Hype Analysis. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.
Altamira |
Altamira Therapeutics Today Top News and Investor Outlook
Altamira Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Altamira and other traded companies coverage with news coverage. We help investors stay connected with Altamira headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Altamira Stock performance. Please note that trading solely based on the Altamira Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Altamira Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Altamira earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Altamira Therapeutics that are available to investors today. That information is available publicly through Altamira media outlets and privately through word of mouth or via Altamira internal channels. However, regardless of the origin, that massive amount of Altamira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Altamira Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Altamira Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Altamira Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Altamira Therapeutics alpha.
Altamira Largest EPS Surprises
Earnings surprises can significantly impact Altamira Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-31 | 2020-12-31 | -1.4 | -0.2869 | 1.1131 | 79 | ||
2020-09-17 | 2020-06-30 | -1.6 | -0.4041 | 1.1959 | 74 | ||
2019-03-14 | 2018-12-31 | -2.2173 | -0.6213 | 1.596 | 71 | ||
2017-11-28 | 2017-09-30 | -33 | -28.0 | 5.0 | 15 | ||
2016-11-10 | 2016-09-30 | -55.65 | -50.0 | 5.65 | 10 | ||
2017-08-10 | 2017-06-30 | -38 | -32.0 | 6.0 | 15 |
Altamira Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Altamira Therapeutics Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
15th of November 2024
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeutics Ltd at gurufocus.com
21st of October 2024
CYTO stock plunges to 52-week low, hitting 0.57 amid market challenges - Investing.com at news.google.com
27th of September 2024
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification... at finance.yahoo.com
25th of September 2024
Altamira Therapeutics Ltd Q2 2024 Earnings Call Transcript Highlights Key Financial and ..... at gurufocus.com
23rd of September 2024
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altam... at kalkinemedia.com
19th of September 2024
Altamira Therapeutics Announces Closing of up to 12.0 Million Public Offering at globenewswire.com
17th of September 2024
Altamira Therapeutics Announces Pricing of up to 12.0 Million Public Offering at globenewswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altamira Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altamira Therapeutics' short interest history, or implied volatility extrapolated from Altamira Therapeutics options trading.
Check out Altamira Therapeutics Backtesting and Altamira Therapeutics Hype Analysis. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.